These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 26317246)

  • 41. Association of -174G/C interleukin/6 gene polymorphism with the risk of chronic lymphocytic, chronic myelogenous and acute myelogenous leukemias in Turkish patients.
    Mutlu P; Yalcin S; Elci P; Yildirim M; Cetin AT; Avcu F
    J BUON; 2014; 19(3):787-91. PubMed ID: 25261668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Array comparative genomic hybridization in pediatric acute leukemias.
    Laskowska J; Szczepanek J; Styczyński J; Tretyn A
    Pediatr Hematol Oncol; 2013 Nov; 30(8):677-87. PubMed ID: 23758127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genomic profiling in high hyperdiploid acute myeloid leukemia: a retrospective study of 19 cases.
    Veigaard C; Nørgaard JM; Kjeldsen E
    Cancer Genet; 2011 Sep; 204(9):516-21. PubMed ID: 22018275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes.
    Jacoby MA; Walter MJ
    Expert Rev Mol Diagn; 2012 Apr; 12(3):253-64. PubMed ID: 22468816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.
    Shi Y; Dong H; Sun S; Wu X; Fang J; Zhao J; Han J; Li Z; Wu H; Liu L; Wu W; Tian Y; Yuan G; Fan X; Xu C
    Clin Mol Hepatol; 2024 Jan; 30(1):80-97. PubMed ID: 38061333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry.
    Li D; Wu J; Liu Z; Qiu L; Zhang Y
    PeerJ; 2020; 8():e9507. PubMed ID: 32704452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma.
    Xue F; Yang L; Dai B; Xue H; Zhang L; Ge R; Sun Y
    PeerJ; 2020; 8():e8301. PubMed ID: 32518711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CFHR1 is a potentially downregulated gene in lung adenocarcinoma.
    Wu G; Yan Y; Wang X; Ren X; Chen X; Zeng S; Wei J; Qian L; Yang X; Ou C; Lin W; Gong Z; Zhou J; Xu Z
    Mol Med Rep; 2019 Oct; 20(4):3642-3648. PubMed ID: 31485643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Array CGH in human leukemia: from somatics to genetics.
    van der Veken LT; Buijs A
    Cytogenet Genome Res; 2011; 135(3-4):260-70. PubMed ID: 21893961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
    Dragon-Durey MA; Blanc C; Marliot F; Loirat C; Blouin J; Sautes-Fridman C; Fridman WH; Frémeaux-Bacchi V
    J Med Genet; 2009 Jul; 46(7):447-50. PubMed ID: 19435718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.
    Zipfel PF; Edey M; Heinen S; Józsi M; Richter H; Misselwitz J; Hoppe B; Routledge D; Strain L; Hughes AE; Goodship JA; Licht C; Goodship TH; Skerka C
    PLoS Genet; 2007 Mar; 3(3):e41. PubMed ID: 17367211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.
    Holmes LV; Strain L; Staniforth SJ; Moore I; Marchbank K; Kavanagh D; Goodship JA; Cordell HJ; Goodship TH
    PLoS One; 2013; 8(4):e60352. PubMed ID: 23613724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
    Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
    Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population.
    Fratelli M; Bolis M; Kurosaki M; Dori M; Guarnaccia V; Spinelli O; Alberti M; Valoti E; Pileggi S; Noris M; Remuzzi G; Rambaldi A; Terao M; Garattini E
    Leuk Lymphoma; 2016 May; 57(5):1234-7. PubMed ID: 26317246
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.